CORDIS

The successful recruitment and incorporation of an Innovation associate (IA), with expertise in live cell imaging, life sciences instrumentation and automation, into the Valitacell team is integral to the evolution of our technologies. The IA will dramatically enhance Valitacells capabilities in this space, strengthen existing collaborations, and generate further opportunities for future innovation. If successful, II-LCA will lead to the accelerated development of novel biological drugs and cellular therapeutics, for the treatment of diverse disease indications. European patients will benefit from increased access to targeted and innovative breakthrough therapies, through reduced cost of development and improved manufacturing paradigms.